Similar articles

• [HLA-restricted cancer-specific killer T cells].

  Harada M, Itoh K. Harada M, et al. Nihon Rinsho. 2005 Apr;63 Suppl 4:579-84. Nihon Rinsho. 2005. PMID: 15861714 Review. Japanese. No abstract available.
• Mechanism of immune escape of cancer and its regulation.

  Morita R, Hirohashi Y, Torigoe T. Morita R, et al. Rinsho Ketsueki. 2009 May;50(5):375-80. Rinsho Ketsueki. 2009. PMID: 19483397 Review. No abstract available.
• [Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"].

  Peiper M, Goedegebuure PS, Eberlein TJ, Zornig C. Peiper M, et al. Zentralbl Chir. 1997;122(3):141-8. Zentralbl Chir. 1997. PMID: 9206906 Review. German.
• Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.

  Toes RE, Offringa R, Feltkamp MC, Visseren MJ, Schoenberger SP, Melief CJ, Kast WM. Toes RE, et al. Behring Inst Mitt. 1994 Jul;(94):72-86. Behring Inst Mitt. 1994. PMID: 7998917 Review.
• In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.

  Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, Parham GP. Santin AD, et al. Am J Obstet Gynecol. 2000 Sep;183(3):601-9. doi: 10.1067/mob.2000.107097. Am J Obstet Gynecol. 2000. PMID: 10992180